{"id":"NCT03248440","sponsor":"Senju USA, Inc.","briefTitle":"Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion","officialTitle":"A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion (SUN-131-03)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-31","primaryCompletion":"2018-08-17","completion":"2018-08-17","firstPosted":"2017-08-14","resultsPosted":"2021-08-05","lastUpdate":"2021-08-05"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chalazion"],"interventions":[{"type":"DRUG","name":"SUN-131 1.5% TDS","otherNames":[]},{"type":"DRUG","name":"Placebo TDS","otherNames":[]}],"arms":[{"label":"SUN-131 1.5% TDS","type":"EXPERIMENTAL"},{"label":"Placebo TDS","type":"PLACEBO_COMPARATOR"}],"summary":"This protocol for SUN-131 1.5% TDS is developed for the treatment of chalazion. SUN-131 1.5% TDS is designed for local delivery of a corticosteroid, to the upper or lower eyelid. The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo TDS in the treatment of a chalazion.","primaryOutcome":{"measure":"The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 ± 1","timeFrame":"Baseline to Day 15 ± 1","effectByArm":[{"arm":"Placebo TDS","deltaMin":28,"sd":null},{"arm":"SUN-131 1.5% TDS","deltaMin":32,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.579"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":65,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":131},"commonTop":["Chalazion","Pruritus","Vision blurred","Pain","Acne"]}}